Page last updated: 2024-12-10

4-hydroxy-2-hexenal

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-hydroxy-2-hexenal: metabolite from senecionine; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5283314
CHEBI ID180385
SCHEMBL ID1269927
MeSH IDM0133338

Synonyms (31)

Synonym
CHEBI:180385
(e)-4-hydroxyhex-2-enal
(e)-4-hydroxy-hex-2-enal
4-hydroxy-2-hexenal
ccris 9201
2-hexenal, 4-hydroxy-
LMFA06000016
4-hydroxy-2e-hexenal
4-hydroxyhexenal
17427-08-6
A810173
160708-91-8
AKOS006273451
17427-21-3
2-hexenal, 4-hydroxy-, (e)-
(e)-4-hydroxy-2-hexenal
(e)-4-hydroxyhexenal
SCHEMBL1269927
JYTUBIHWMKQZRB-ONEGZZNKSA-N
HMS3648N12
J-009747
(2e)-4-hydroxy-2-hexenal
sr-01000946533
SR-01000946533-1
2-hexenal, 4-hydroxy-, (2e)-
DTXSID701313524
(2e)-4-hydroxyhex-2-enal
4-hydroxy hexenal
4-hhe
STARBLD0042458
PD021011

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The present study aimed to investigate the dose-response effects of LC n-3 PUFA on the production of peroxidised metabolites, as potential bioactive molecules, and on global gene expression in liver."( Increasing intake of long-chain n-3 PUFA enhances lipoperoxidation and modulates hepatic gene expression in a dose-dependent manner.
Chardigny, JM; Comte, B; Da Silva, G; Feillet-Coudray, C; Gladine, C; Joly, C; Laillet, B; McNabb, WC; Morio, B; Pujos-Guillot, E; Rigaudière, JP; Roy, NC, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
fatty aldehydeAn aldehyde formally arising from reduction of the carboxylic acid group of its corresponding fatty acid, having a carbonyl group at one end of the carbon chain.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (100)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (8.00)18.7374
1990's10 (10.00)18.2507
2000's29 (29.00)29.6817
2010's47 (47.00)24.3611
2020's6 (6.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.91 (24.57)
Research Supply Index4.64 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.98%)5.53%
Reviews3 (2.94%)6.00%
Case Studies1 (0.98%)4.05%
Observational0 (0.00%)0.25%
Other97 (95.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]